Skip to main content
Top
Published in: BMC Cancer 1/2012

Open Access 01-12-2012 | Research article

GLUT1 expression patterns in different Hodgkin lymphoma subtypes and progressively transformed germinal centers

Authors: Sylvia Hartmann, Claudio Agostinelli, Jürgen Diener, Claudia Döring, Stefano Fanti, Pier Luigi Zinzani, Andrea Gallamini, Lothar Bergmann, Stefano Pileri, Martin-Leo Hansmann

Published in: BMC Cancer | Issue 1/2012

Login to get access

Abstract

Background

Increased glycolytic activity is a hallmark of cancer, allowing staging and restaging with 18F-fluorodeoxyglucose-positron-emission-tomography (PET). Since interim-PET is an important prognostic tool in Hodgkin lymphoma (HL), the aim of this study was to investigate the expression of proteins involved in the regulation of glucose metabolism in the different HL subtypes and their impact on clinical outcome.

Methods

Lymph node biopsies from 54 HL cases and reactive lymphoid tissue were stained for glucose transporter 1 (GLUT1), lactate dehydrogenase A (LDHA) and lactate exporter proteins MCT1 and MCT4. In a second series, samples from additional 153 HL cases with available clinical data were stained for GLUT1 and LDHA.

Results

Membrane bound GLUT1 expression was frequently observed in the tumor cells of HL (49% of all cases) but showed a broad variety between the different Hodgkin lymphoma subtypes: Nodular sclerosing HL subtype displayed a membrane bound GLUT1 expression in the Hodgkin-and Reed-Sternberg cells in 56% of the cases. However, membrane bound GLUT1 expression was more rarely observed in tumor cells of lymphocyte rich classical HL subtype (30%) or nodular lymphocyte predominant HL subtype (15%). Interestingly, in both of these lymphocyte rich HL subtypes as well as in progressively transformed germinal centers, reactive B cells displayed strong expression of GLUT1. LDHA, acting downstream of glycolysis, was also expressed in 44% of all cases. We evaluated the prognostic value of different GLUT1 and LDHA expression patterns; however, no significant differences in progression free or overall survival were found between patients exhibiting different GLUT1 or LDHA expression patterns. There was no correlation between GLUT1 expression in HRS cells and PET standard uptake values.

Conclusions

In a large number of cases, HRS cells in classical HL express high levels of GLUT1 and LDHA indicating glycolytic activity in the tumor cells. Although interim-PET is an important prognostic tool, a predictive value of GLUT1 or LDHA staining of the primary diagnostic biopsy could not be demonstrated. However, we observed GLUT1 expression in progressively transformed germinal centers and hyperplastic follicles, explaining false positive results in PET. Therefore, PET findings suggestive of HL relapse should always be confirmed by histology.
Appendix
Available only for authorised users
Literature
1.
go back to reference Küppers R, Rajewsky K, Zhao M, Simons G, Laumann R, Fischer R, et al: Hodgkin disease: Hodgkin and reed-Sternberg cells picked from histological sections show clonal immunoglobulin gene rearrangements and appear to be derived from B cells at various stages of development. Proc Natl Acad Sci USA. 1994, 91: 10962-10966. 10.1073/pnas.91.23.10962.CrossRefPubMedPubMedCentral Küppers R, Rajewsky K, Zhao M, Simons G, Laumann R, Fischer R, et al: Hodgkin disease: Hodgkin and reed-Sternberg cells picked from histological sections show clonal immunoglobulin gene rearrangements and appear to be derived from B cells at various stages of development. Proc Natl Acad Sci USA. 1994, 91: 10962-10966. 10.1073/pnas.91.23.10962.CrossRefPubMedPubMedCentral
2.
go back to reference Schwering I, Bräuninger A, Klein U, Jungnickel B, Tinguely M, Diehl V, et al: Loss of the B-lineage-specific gene expression program in Hodgkin and reed-Sternberg cells of Hodgkin lymphoma. Blood. 2003, 101: 1505-1512. 10.1182/blood-2002-03-0839.CrossRefPubMed Schwering I, Bräuninger A, Klein U, Jungnickel B, Tinguely M, Diehl V, et al: Loss of the B-lineage-specific gene expression program in Hodgkin and reed-Sternberg cells of Hodgkin lymphoma. Blood. 2003, 101: 1505-1512. 10.1182/blood-2002-03-0839.CrossRefPubMed
3.
go back to reference Swerdlow SH, International Agency for Research on Cancer: World Health Organization. WHO classification of tumours of haematopoietic and lymphoid tissues. 2008, Lyon, France: International Agency for Research on Cancer, 4 Swerdlow SH, International Agency for Research on Cancer: World Health Organization. WHO classification of tumours of haematopoietic and lymphoid tissues. 2008, Lyon, France: International Agency for Research on Cancer, 4
4.
go back to reference Mathas S, Lietz A, Janz M, Hinz M, Jundt F, Scheidereit C, et al: Inhibition of NF-kappaB essentially contributes to arsenic-induced apoptosis. Blood. 2003, 102: 1028-1034. 10.1182/blood-2002-04-1154.CrossRefPubMed Mathas S, Lietz A, Janz M, Hinz M, Jundt F, Scheidereit C, et al: Inhibition of NF-kappaB essentially contributes to arsenic-induced apoptosis. Blood. 2003, 102: 1028-1034. 10.1182/blood-2002-04-1154.CrossRefPubMed
5.
go back to reference Dutton A, Reynolds GM, Dawson CW, Young LS, Murray PG: Constitutive activation of phosphatidyl-inositide 3 kinase contributes to the survival of Hodgkin's lymphoma cells through a mechanism involving Akt kinase and mTOR. J Pathol. 2005, 205: 498-506. 10.1002/path.1725.CrossRefPubMed Dutton A, Reynolds GM, Dawson CW, Young LS, Murray PG: Constitutive activation of phosphatidyl-inositide 3 kinase contributes to the survival of Hodgkin's lymphoma cells through a mechanism involving Akt kinase and mTOR. J Pathol. 2005, 205: 498-506. 10.1002/path.1725.CrossRefPubMed
6.
go back to reference Jundt F, Anagnostopoulos I, Forster R, Mathas S, Stein H, Dorken B: Activated Notch1 signaling promotes tumor cell proliferation and survival in Hodgkin and anaplastic large cell lymphoma. Blood. 2002, 99: 3398-3403. 10.1182/blood.V99.9.3398.CrossRefPubMed Jundt F, Anagnostopoulos I, Forster R, Mathas S, Stein H, Dorken B: Activated Notch1 signaling promotes tumor cell proliferation and survival in Hodgkin and anaplastic large cell lymphoma. Blood. 2002, 99: 3398-3403. 10.1182/blood.V99.9.3398.CrossRefPubMed
7.
go back to reference Emmerich F, Meiser M, Hummel M, Demel G, Foss HD, Jundt F, et al: Overexpression of I kappa B alpha without inhibition of NF-kappaB activity and mutations in the I kappa B alpha gene in Reed-Sternberg cells. Blood. 1999, 94: 3129-3134.PubMed Emmerich F, Meiser M, Hummel M, Demel G, Foss HD, Jundt F, et al: Overexpression of I kappa B alpha without inhibition of NF-kappaB activity and mutations in the I kappa B alpha gene in Reed-Sternberg cells. Blood. 1999, 94: 3129-3134.PubMed
8.
go back to reference Skinnider BF, Elia AJ, Gascoyne RD, Patterson B, Trümper L, Kapp U, et al: Signal transducer and activator of transcription 6 is frequently activated in Hodgkin and Reed-Sternberg cells of Hodgkin lymphoma. Blood. 2002, 99: 618-626. 10.1182/blood.V99.2.618.CrossRefPubMed Skinnider BF, Elia AJ, Gascoyne RD, Patterson B, Trümper L, Kapp U, et al: Signal transducer and activator of transcription 6 is frequently activated in Hodgkin and Reed-Sternberg cells of Hodgkin lymphoma. Blood. 2002, 99: 618-626. 10.1182/blood.V99.2.618.CrossRefPubMed
10.
go back to reference Ward PS, Thompson CB: Metabolic reprogramming: a cancer hallmark even warburg did not anticipate. Cancer Cell. 2012, 21: 297-308. 10.1016/j.ccr.2012.02.014.CrossRefPubMedPubMedCentral Ward PS, Thompson CB: Metabolic reprogramming: a cancer hallmark even warburg did not anticipate. Cancer Cell. 2012, 21: 297-308. 10.1016/j.ccr.2012.02.014.CrossRefPubMedPubMedCentral
11.
go back to reference Gatenby RA, Gillies RJ: Why do cancers have high aerobic glycolysis?. Nat Rev Cancer. 2004, 4: 891-899. 10.1038/nrc1478.CrossRefPubMed Gatenby RA, Gillies RJ: Why do cancers have high aerobic glycolysis?. Nat Rev Cancer. 2004, 4: 891-899. 10.1038/nrc1478.CrossRefPubMed
12.
go back to reference Hueltenschmidt B, Sautter-Bihl ML, Lang O, Maul FD, Fischer J, Mergenthaler HG, et al: Whole body positron emission tomography in the treatment of Hodgkin disease. Cancer. 2001, 91: 302-310. 10.1002/1097-0142(20010115)91:2<302::AID-CNCR1002>3.0.CO;2-4.CrossRefPubMed Hueltenschmidt B, Sautter-Bihl ML, Lang O, Maul FD, Fischer J, Mergenthaler HG, et al: Whole body positron emission tomography in the treatment of Hodgkin disease. Cancer. 2001, 91: 302-310. 10.1002/1097-0142(20010115)91:2<302::AID-CNCR1002>3.0.CO;2-4.CrossRefPubMed
13.
go back to reference Hutchings M, Loft A, Hansen M, Ralfkiaer E, Specht L: Different histopathological subtypes of Hodgkin lymphoma show significantly different levels of FDG uptake. Hematol Oncol. 2006, 24: 146-150. 10.1002/hon.782.CrossRefPubMed Hutchings M, Loft A, Hansen M, Ralfkiaer E, Specht L: Different histopathological subtypes of Hodgkin lymphoma show significantly different levels of FDG uptake. Hematol Oncol. 2006, 24: 146-150. 10.1002/hon.782.CrossRefPubMed
14.
go back to reference Le Roux PY, Gastinne T, Le Gouill S, Nowak E, Bodet-Milin C, Querellou S, et al: Prognostic value of interim FDG PET/CT in Hodgkin's lymphoma patients treated with interim response-adapted strategy: comparison of International Harmonization Project (IHP), Gallamini and London criteria. Eur J Nucl Med Mol Imaging. 2011, 38: 1064-1071. 10.1007/s00259-011-1741-0.CrossRefPubMed Le Roux PY, Gastinne T, Le Gouill S, Nowak E, Bodet-Milin C, Querellou S, et al: Prognostic value of interim FDG PET/CT in Hodgkin's lymphoma patients treated with interim response-adapted strategy: comparison of International Harmonization Project (IHP), Gallamini and London criteria. Eur J Nucl Med Mol Imaging. 2011, 38: 1064-1071. 10.1007/s00259-011-1741-0.CrossRefPubMed
15.
go back to reference Gallamini A, O'Doherty M: Report of satellite workshop on interim-PET in Hodgkin lymphoma: 8th international symposium on Hodgkin lymphoma, cologne, 23 October 2010. Leuk Lymphoma. 2011, 52: 583-586. 10.3109/10428194.2010.551162.CrossRefPubMed Gallamini A, O'Doherty M: Report of satellite workshop on interim-PET in Hodgkin lymphoma: 8th international symposium on Hodgkin lymphoma, cologne, 23 October 2010. Leuk Lymphoma. 2011, 52: 583-586. 10.3109/10428194.2010.551162.CrossRefPubMed
16.
go back to reference Meignan M, Gallamini A, Itti E, Barrington S, Haioun C, Polliack A: Report on the Third International Workshop on Interim Positron Emission Tomography in Lymphoma held in Menton, France, 26-27 September 2011 and Menton 2011 consensus. Leuk Lymphoma. 2012, 53 (10): 1876-1881. 10.3109/10428194.2012.677535. Epub 2012 Apr 23. PMID: 22432519CrossRefPubMed Meignan M, Gallamini A, Itti E, Barrington S, Haioun C, Polliack A: Report on the Third International Workshop on Interim Positron Emission Tomography in Lymphoma held in Menton, France, 26-27 September 2011 and Menton 2011 consensus. Leuk Lymphoma. 2012, 53 (10): 1876-1881. 10.3109/10428194.2012.677535. Epub 2012 Apr 23. PMID: 22432519CrossRefPubMed
17.
go back to reference Brown RS, Wahl RL: Overexpression of Glut-1 glucose transporter in human breast cancer. An immunohistochemical study. Cancer. 1993, 72: 2979-2985. 10.1002/1097-0142(19931115)72:10<2979::AID-CNCR2820721020>3.0.CO;2-X.CrossRefPubMed Brown RS, Wahl RL: Overexpression of Glut-1 glucose transporter in human breast cancer. An immunohistochemical study. Cancer. 1993, 72: 2979-2985. 10.1002/1097-0142(19931115)72:10<2979::AID-CNCR2820721020>3.0.CO;2-X.CrossRefPubMed
18.
go back to reference Cantuaria G, Fagotti A, Ferrandina G, Magalhaes A, Nadji M, Angioli R, et al: GLUT-1 expression in ovarian carcinoma: association with survival and response to chemotherapy. Cancer. 2001, 92: 1144-1150. 10.1002/1097-0142(20010901)92:5<1144::AID-CNCR1432>3.0.CO;2-T.CrossRefPubMed Cantuaria G, Fagotti A, Ferrandina G, Magalhaes A, Nadji M, Angioli R, et al: GLUT-1 expression in ovarian carcinoma: association with survival and response to chemotherapy. Cancer. 2001, 92: 1144-1150. 10.1002/1097-0142(20010901)92:5<1144::AID-CNCR1432>3.0.CO;2-T.CrossRefPubMed
19.
go back to reference Uldry M, Thorens B: The SLC2 family of facilitated hexose and polyol transporters. Pflugers Arch. 2004, 447: 480-489. 10.1007/s00424-003-1085-0.CrossRefPubMed Uldry M, Thorens B: The SLC2 family of facilitated hexose and polyol transporters. Pflugers Arch. 2004, 447: 480-489. 10.1007/s00424-003-1085-0.CrossRefPubMed
20.
go back to reference Khandani AH, Dunphy CH, Meteesatien P, Dufault DL, Ivanovic M, Shea TC: Glut1 and Glut3 expression in lymphoma and their association with tumor intensity on 18F-fluorodeoxyglucose positron emission tomography. Nucl Med Commun. 2009, 30: 594-601. 10.1097/MNM.0b013e32832cc295.CrossRefPubMed Khandani AH, Dunphy CH, Meteesatien P, Dufault DL, Ivanovic M, Shea TC: Glut1 and Glut3 expression in lymphoma and their association with tumor intensity on 18F-fluorodeoxyglucose positron emission tomography. Nucl Med Commun. 2009, 30: 594-601. 10.1097/MNM.0b013e32832cc295.CrossRefPubMed
21.
go back to reference Shim HK, Lee WW, Park SY, Kim H, Kim SE: Relationship between FDG uptake and expressions of glucose transporter type 1, type 3, and hexokinase-II in Reed-Sternberg cells of Hodgkin lymphoma. Oncol Res. 2009, 17: 331-337. 10.3727/096504009787721177.CrossRefPubMed Shim HK, Lee WW, Park SY, Kim H, Kim SE: Relationship between FDG uptake and expressions of glucose transporter type 1, type 3, and hexokinase-II in Reed-Sternberg cells of Hodgkin lymphoma. Oncol Res. 2009, 17: 331-337. 10.3727/096504009787721177.CrossRefPubMed
22.
go back to reference Shim HK, Lee WW, Park SY, Kim H, So Y, Kim SE: Expressions of glucose transporter Types 1 and 3 and hexokinase-II in diffuse large B-cell lymphoma and other B-cell non-Hodgkin's lymphomas. Nucl Med Biol. 2009, 36: 191-197. 10.1016/j.nucmedbio.2008.11.009.CrossRefPubMed Shim HK, Lee WW, Park SY, Kim H, So Y, Kim SE: Expressions of glucose transporter Types 1 and 3 and hexokinase-II in diffuse large B-cell lymphoma and other B-cell non-Hodgkin's lymphomas. Nucl Med Biol. 2009, 36: 191-197. 10.1016/j.nucmedbio.2008.11.009.CrossRefPubMed
23.
go back to reference Kaira K, Abe M, Nakagawa K, Ohde Y, Okumura T, Takahashi T, Murakami H, Shukuya T, Kenmotsu H, Naito T, Hayashi I, Oriuchi N, Endo M, Kondo H, Nakajima T, Yamamoto N: 18F-FDG uptake on PET in primary mediastinal non-thymic neoplasm: a clinicopathological study. Eur J Radiol. 2012, 81 (9): 2423-2429. 10.1016/j.ejrad.2011.09.017. Epub 2011 Nov 4. PMID: 22055682CrossRefPubMed Kaira K, Abe M, Nakagawa K, Ohde Y, Okumura T, Takahashi T, Murakami H, Shukuya T, Kenmotsu H, Naito T, Hayashi I, Oriuchi N, Endo M, Kondo H, Nakajima T, Yamamoto N: 18F-FDG uptake on PET in primary mediastinal non-thymic neoplasm: a clinicopathological study. Eur J Radiol. 2012, 81 (9): 2423-2429. 10.1016/j.ejrad.2011.09.017. Epub 2011 Nov 4. PMID: 22055682CrossRefPubMed
24.
go back to reference Ganapathy V, Thangaraju M, Prasad PD: Nutrient transporters in cancer: relevance to Warburg hypothesis and beyond. Pharmacol Ther. 2009, 121: 29-40. 10.1016/j.pharmthera.2008.09.005.CrossRefPubMed Ganapathy V, Thangaraju M, Prasad PD: Nutrient transporters in cancer: relevance to Warburg hypothesis and beyond. Pharmacol Ther. 2009, 121: 29-40. 10.1016/j.pharmthera.2008.09.005.CrossRefPubMed
25.
go back to reference Renné C, Willenbrock K, Küppers R, Hansmann M-L, Bräuninger A: Autocrine and paracrine activated receptor tyrosine kinases in classical Hodgkin lymphoma. Blood. 2005, 105: 4051-4059. 10.1182/blood-2004-10-4008.CrossRefPubMed Renné C, Willenbrock K, Küppers R, Hansmann M-L, Bräuninger A: Autocrine and paracrine activated receptor tyrosine kinases in classical Hodgkin lymphoma. Blood. 2005, 105: 4051-4059. 10.1182/blood-2004-10-4008.CrossRefPubMed
26.
go back to reference R Development Core Team: R: A Language and Environment for Statistical Computing. 2012, Vienna, Austria: R Foundation for Statistical Computing R Development Core Team: R: A Language and Environment for Statistical Computing. 2012, Vienna, Austria: R Foundation for Statistical Computing
27.
go back to reference Kaplan ELMP: Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958, 53: 457-481. 10.1080/01621459.1958.10501452.CrossRef Kaplan ELMP: Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958, 53: 457-481. 10.1080/01621459.1958.10501452.CrossRef
28.
go back to reference Grigg A, Ganju V: PET positive progressive transformation of germinal centers masquerading as relapsed Hodgkin lymphoma post-autograft. Leuk Lymphoma. 2006, 47: 764-765.CrossRefPubMed Grigg A, Ganju V: PET positive progressive transformation of germinal centers masquerading as relapsed Hodgkin lymphoma post-autograft. Leuk Lymphoma. 2006, 47: 764-765.CrossRefPubMed
29.
go back to reference Levine JM, Weiner M, Kelly KM: Routine use of PET scans after completion of therapy in pediatric Hodgkin disease results in a high false positive rate. J Pediatr Hematol Oncol. 2006, 28: 711-714. 10.1097/01.mph.0000243648.66734.eb.CrossRefPubMed Levine JM, Weiner M, Kelly KM: Routine use of PET scans after completion of therapy in pediatric Hodgkin disease results in a high false positive rate. J Pediatr Hematol Oncol. 2006, 28: 711-714. 10.1097/01.mph.0000243648.66734.eb.CrossRefPubMed
30.
go back to reference Ansquer C, Hervouet T, Devillers A, de Guibert S, Gastinne T, Le Gouill S, et al: 18-F FDG-PET in the staging of lymphocyte-predominant Hodgkin's disease. Haematologica. 2008, 93: 128-131. 10.3324/haematol.11661.CrossRefPubMed Ansquer C, Hervouet T, Devillers A, de Guibert S, Gastinne T, Le Gouill S, et al: 18-F FDG-PET in the staging of lymphocyte-predominant Hodgkin's disease. Haematologica. 2008, 93: 128-131. 10.3324/haematol.11661.CrossRefPubMed
31.
go back to reference Tohma T, Okazumi S, Makino H, Cho A, Mochizuki R, Shuto K, et al: Overexpression of glucose transporter 1 in esophageal squamous cell carcinomas: a marker for poor prognosis. Dis Esophagus. 2005, 18: 185-189. 10.1111/j.1442-2050.2005.00489.x.CrossRefPubMed Tohma T, Okazumi S, Makino H, Cho A, Mochizuki R, Shuto K, et al: Overexpression of glucose transporter 1 in esophageal squamous cell carcinomas: a marker for poor prognosis. Dis Esophagus. 2005, 18: 185-189. 10.1111/j.1442-2050.2005.00489.x.CrossRefPubMed
32.
go back to reference Mori Y, Tsukinoki K, Yasuda M, Miyazawa M, Kaneko A, Watanabe Y: Glucose transporter type 1 expression are associated with poor prognosis in patients with salivary gland tumors. Oral Oncol. 2007, 43: 563-569. 10.1016/j.oraloncology.2006.06.006.CrossRefPubMed Mori Y, Tsukinoki K, Yasuda M, Miyazawa M, Kaneko A, Watanabe Y: Glucose transporter type 1 expression are associated with poor prognosis in patients with salivary gland tumors. Oral Oncol. 2007, 43: 563-569. 10.1016/j.oraloncology.2006.06.006.CrossRefPubMed
33.
go back to reference Maratou E, Dimitriadis G, Kollias A, Boutati E, Lambadiari V, Mitrou P, et al: Glucose transporter expression on the plasma membrane of resting and activated white blood cells. Eur J Clin Invest. 2007, 37: 282-290. 10.1111/j.1365-2362.2007.01786.x.CrossRefPubMed Maratou E, Dimitriadis G, Kollias A, Boutati E, Lambadiari V, Mitrou P, et al: Glucose transporter expression on the plasma membrane of resting and activated white blood cells. Eur J Clin Invest. 2007, 37: 282-290. 10.1111/j.1365-2362.2007.01786.x.CrossRefPubMed
34.
go back to reference Itoh K, Kinoshita T, Watanabe T, Yoshimura K, Okamoto R, Chou T, et al: Prognostic analysis and a new risk model for Hodgkin lymphoma in Japan. Int J Hematol. 2010, 91: 446-455. 10.1007/s12185-010-0533-9.CrossRefPubMed Itoh K, Kinoshita T, Watanabe T, Yoshimura K, Okamoto R, Chou T, et al: Prognostic analysis and a new risk model for Hodgkin lymphoma in Japan. Int J Hematol. 2010, 91: 446-455. 10.1007/s12185-010-0533-9.CrossRefPubMed
35.
go back to reference Lambert DW, Wood IS, Ellis A, Shirazi-Beechey SP: Molecular changes in the expression of human colonic nutrient transporters during the transition from normality to malignancy. Br J Cancer. 2002, 86: 1262-1269. 10.1038/sj.bjc.6600264.CrossRefPubMedPubMedCentral Lambert DW, Wood IS, Ellis A, Shirazi-Beechey SP: Molecular changes in the expression of human colonic nutrient transporters during the transition from normality to malignancy. Br J Cancer. 2002, 86: 1262-1269. 10.1038/sj.bjc.6600264.CrossRefPubMedPubMedCentral
Metadata
Title
GLUT1 expression patterns in different Hodgkin lymphoma subtypes and progressively transformed germinal centers
Authors
Sylvia Hartmann
Claudio Agostinelli
Jürgen Diener
Claudia Döring
Stefano Fanti
Pier Luigi Zinzani
Andrea Gallamini
Lothar Bergmann
Stefano Pileri
Martin-Leo Hansmann
Publication date
01-12-2012
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2012
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-12-586

Other articles of this Issue 1/2012

BMC Cancer 1/2012 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine